These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19135118)

  • 41. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
    Kelleher AD; Puls RL; Bebbington M; Boyle D; Ffrench R; Kent SJ; Kippax S; Purcell DF; Thomson S; Wand H; Cooper DA; Emery S
    AIDS; 2006 Jan; 20(2):294-7. PubMed ID: 16511428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype.
    Neeson P; Boyer J; Kumar S; Lewis MG; Mattias L; Veazey R; Weiner D; Paterson Y
    Virology; 2006 Oct; 354(2):299-315. PubMed ID: 16904153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
    Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
    Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
    Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.
    Dai K; Liu Y; Liu M; Xu J; Huang W; Huang X; Liu L; Wan Y; Hao Y; Shao Y
    Vaccine; 2008 Sep; 26(39):5062-71. PubMed ID: 18573290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.
    Bolton DL; Santra S; Swett-Tapia C; Custers J; Song K; Balachandran H; Mach L; Naim H; Kozlowski PA; Lifton M; Goudsmit J; Letvin N; Roederer M; Radošević K
    Vaccine; 2012 Sep; 30(41):5991-8. PubMed ID: 22732429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.
    Bivas-Benita M; Lin MY; Bal SM; van Meijgaarden KE; Franken KL; Friggen AH; Junginger HE; Borchard G; Klein MR; Ottenhoff TH
    Vaccine; 2009 Jun; 27(30):4010-7. PubMed ID: 19389445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection.
    Quintana-Vázquez D; Vázquez-Blomquist DM; Galbán Rodríguez E; Herrera Buch AM; Duarte Cano CA
    Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):59-66. PubMed ID: 15099194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A model for testing the immunogenicity of simian immunodeficiency virus and simian-human immunodeficiency virus vaccine candidates in mice.
    Xu J; Kelly M; Denning W; Hel Z
    J Virol Methods; 2009 Jun; 158(1-2):70-6. PubMed ID: 19428572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SIVmac Gag p27 capsid protein gene expression in potato.
    Kim TG; Ruprecht R; Langridge WH
    Protein Expr Purif; 2004 Aug; 36(2):312-7. PubMed ID: 15249055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles.
    Halsey RJ; Tanzer FL; Meyers A; Pillay S; Lynch A; Shephard E; Williamson AL; Rybicki EP
    Virus Res; 2008 May; 133(2):259-68. PubMed ID: 18329748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses.
    Huang X; Xu J; Qiu C; Ren L; Liu L; Wan Y; Zhang N; Peng H; Shao Y
    Vaccine; 2007 Mar; 25(14):2620-9. PubMed ID: 17280743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Construction of recombinant vaccinia virus expressing HPV18E7E6 fusion proteins and detection of its immunogenicity in mice].
    Zhao L; Ren J; Feng J; Gao J; Zhang H; Tian HW; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):189-91. PubMed ID: 19031699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice].
    Liu XL; Yu SQ; Feng X; Wang XL; Liu HM; Zhang XM; Li HX; Zhou L; Li ZL; Zheng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):5-7. PubMed ID: 17429520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens.
    Center RJ; Wheatley AK; Campbell SM; Gaeguta AJ; Peut V; Alcantara S; Siebentritt C; Kent SJ; Purcell DF
    Vaccine; 2009 Nov; 27(47):6605-12. PubMed ID: 19712773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aids vaccine advance.
    Novak K; MacFarlane J; Aamodt S
    Nat Med; 2000 Nov; 6(11):1220. PubMed ID: 11062531
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of a Clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine.
    Chen Y; Helmus R; McClane B; Hoffman R; Watkins S; Wehrli T; Gupta P
    Virology; 2004 Nov; 329(2):226-33. PubMed ID: 15518803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.